VBI VACCINES INC (VBIV)
CA91822J2020 - Common Stock
VBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023
VBIV stock results show that VBI Vaccines beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
VBI Vaccines Reports Full Year 2023 Financial Results
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to dive into all of the biggest pre-market stock movers that traders will want to keep an eye on Friday morning!
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational...
VBI signs deal to sell manufacturing capabilities, certain assets with Brii Biosciences
Biopharmaceutical firm VBI Vaccines rose over 7% in premarket trading as Brii Biosciences announced the acquisition of VBI's HBV immunotherapeutic...
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain...
VBI Vaccines Reports Third Quarter 2023 Financial Results
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
VBI Vaccines stock gains after data for Hep B candidate
Read why VBI Vaccines (VBIV) traded higher Wednesday after its partner Brii Biosciences Limited (BRIBF), announced mid-stage data for Hep B drug BRII-179.
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve...
VBI Vaccines Reports Second Quarter 2023 Financial Results
VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares
VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
7 Biotech Stocks to Sell in July
Running the gamut from large to small, and from commercial stage to clinical stage, these are seven top biotech stocks to sell in July.
Why Is Kazia Therapeutics (KZIA) Stock Moving Today?
Kazia Therapeutics (KZIA) stock is on the move Thursday after the company received fast-track designation for its paxalisib program.
VBI Vaccines slides on discounted stock and warrants offering (NASDAQ:VBIV)
Shares of VBI Vaccines (VBIV) tumbled 51.7% to $1.17 on Thursday after pricing its underwritten public offering and concurrent registered direct offering to cumulatively raise...